{"denoms":[{"counts":[{"groupId":"BG000","value":"215"}],"units":"Participants"}],"groups":[{"description":"Participants who had received at least 2 years of first-line nilotinib treatment and achieved a deep molecular response (MR4.5) entered the nilotinib treatment consolidation (NTCS) phase. During this phase, participants received nilotinib 300 mg twice daily for 52 weeks.","id":"BG000","title":"NTCS Phase"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"21","upperLimit":"86","value":"54.0"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"102"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"113"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"189"}]}],"title":"Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}]}],"title":"Unknown"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Native American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"}]}